NasdaqCM - Nasdaq Real Time Price USD

Precipio, Inc. (PRPO)

6.00

-0.18

(-2.91%)

At close: January 13 at 4:00:00 PM EST

Two Smaller Companies Worthy of Your "Attention"

Here we highlight a small cap and a microcap with Zacks Outperform ratings.

Zacks last month

^GSPC

PRPO
-2.91%
Precipio Inc (PRPO) Q3 2024 Earnings Call Highlights: Strong Growth in Diagnostic Services and ...

Precipio Inc (PRPO) reports significant milestones with increased revenues and reduced cash burn, while addressing challenges in product division profitability and investor education.

GuruFocus.com last month

PRPO
-2.91%
Precipio Third Quarter 2024 Earnings: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)

Precipio ( NASDAQ:PRPO ) Third Quarter 2024 Results Key Financial Results Revenue: US$5.21m (up 15% from 3Q 2023). Net...

Simply Wall St. 2 months ago

PRPO
-2.91%
Precipio Announces Q3-2024 Shareholder Update Call

Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The conference call may be accessed by calling 844-695-5519 (international callers

GlobeNewswire 2 months ago

PRPO
-2.91%
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patientsNEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-mak

GlobeNewswire 3 months ago

PRPO
-2.91%
Precipio Announces Employee Stock Option Plan Repricing

Management lays out rationale and impact to shareholders belowNEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company’s repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely c

GlobeNewswire 4 months ago

PRPO
-2.91%
Zacks Initiates Coverage of Precipio With Outperform Recommendation

Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space.

Zacks 4 months ago

PRPO
-2.91%
Precipio Announces Q2-2024 Shareholder Update Call

Conference Call to be held on August 19, 2024 at 5:00 PM EDTNEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET. The call will include updates on the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. P

GlobeNewswire 4 months ago

PRPO
-2.91%
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

Company’s continued growth and improved cash position alleviates the need for capital raise in the foreseeable futureNEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were exp

GlobeNewswire 5 months ago

PRPO
-2.91%
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

Pathology Revenues in June exceed breakeven target and continue growth trendNEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division’s

GlobeNewswire 5 months ago

PRPO
-2.91%
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern TimeNEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted, due to lack of the required quorum. Message from Ilan Danieli, CEO: During this process, we’ve realized that there are quite a few shareholders who didn’t know wh

GlobeNewswire 6 months ago

PRPO
-2.91%
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

The cost of a rescheduled shareholder meeting could reach $100,000NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to ensure that there is a quorum required for the shareholders’ meeting that is scheduled to take place tomorrow June 13, 2024 at 10 a.m. Eastern Time. At the time o

GlobeNewswire 6 months ago

PRPO
-2.91%
Precipio Provides Status Update on Current Business Matters

NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) provides the following update to its shareholders on various business matters looking towards mid-year. 1. Business growthIn September of 2023, Precipio’s pathology division exceeded its breakeven point of $15M annualized revenue run rate, resulting in a Q4 cash burn of less than $100K for the quarter. In the following quarter, as previously discussed, due to sever

GlobeNewswire 6 months ago

PRPO
-2.91%
It's Probably Less Likely That Precipio, Inc.'s (NASDAQ:PRPO) CEO Will See A Huge Pay Rise This Year

Key Insights Precipio to hold its Annual General Meeting on 13th of June CEO Ilan Danieli's total compensation includes...

Simply Wall St. 7 months ago

PRPO
-2.91%
Precipio Secures a short-term $500K Credit Facility

Loan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attackNEW HAVEN, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces it has secured a short-term loan facility of $500K to deal with any delays in cash collections due to the recent cybersecurity attack on Change Healthcare, a healthcare billing company used by a significant part of the healthcare market. Ma

GlobeNewswire 8 months ago

PRPO
-2.91%
Precipio Announces Year end 2023 Shareholder Update Call

Conference Call to be held on April 1st, 2024 at 5:00 PM EDTNEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc.

GlobeNewswire 9 months ago

PRPO
-2.91%
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

Company continues to make strides towards breakevenNEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year. Both pathology and products divisions have demonstrated substantial growth from 2023, with the pathology services division increasing revenue by 52%, and the products division incr

GlobeNewswire 10 months ago

PRPO
-2.91%
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physicia

GlobeNewswire 11 months ago

PRPO
-2.91%
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Results clearly demonstrate the business’s ability to reach breakeven in the near futureNEW HAVEN, Conn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that continued revenue growth generated cash levels that bring the company closer to breakeven. Cash Burn From Operations (CBFO) declined by over 90% from the previous quarter, from approximately $1M/quarter in Q3-2023 to below $100k/quarter in the following recent quarter Q4-2023.

GlobeNewswire 11 months ago

PRPO
-2.91%
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

First order for IV-Cell placed by Major Japanese LaboratoryNEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the sales and distribution of its products into the Japanese market. The distributor has already secured its first purchase order from a leading Japanese clinical laboratory, for Precipio’s proprietary IV-Cell cytogenetics media. The first shipmen

GlobeNewswire 11 months ago

PRPO
-2.91%

Performance Overview

Return	PRPO	S&P 500
YTD	+3.45%	-1.20%
1-Year	+12.15%	+22.00%
3-Year	-80.89%	+23.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Precipio, Inc. (PRPO)

Two Smaller Companies Worthy of Your "Attention"

Precipio Inc (PRPO) Q3 2024 Earnings Call Highlights: Strong Growth in Diagnostic Services and ...

Precipio Third Quarter 2024 Earnings: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)

Precipio Announces Q3-2024 Shareholder Update Call

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

Precipio Announces Employee Stock Option Plan Repricing

Zacks Initiates Coverage of Precipio With Outperform Recommendation

Precipio Announces Q2-2024 Shareholder Update Call

Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Precipio Provides Status Update on Current Business Matters

It's Probably Less Likely That Precipio, Inc.'s (NASDAQ:PRPO) CEO Will See A Huge Pay Rise This Year

Precipio Secures a short-term $500K Credit Facility

Precipio Announces Year end 2023 Shareholder Update Call

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

Performance Overview